Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALLO |
---|---|---|
09:32 ET | 27928 | 2.97 |
09:34 ET | 1229 | 2.9506 |
09:36 ET | 35537 | 2.975 |
09:38 ET | 20126 | 2.905 |
09:39 ET | 12413 | 2.9303 |
09:41 ET | 3517 | 2.935 |
09:43 ET | 15052 | 2.9637 |
09:45 ET | 2339 | 2.945 |
09:48 ET | 6065 | 2.93 |
09:50 ET | 2617 | 2.925 |
09:52 ET | 2045 | 2.9207 |
09:54 ET | 3881 | 2.92 |
09:56 ET | 14319 | 2.905 |
09:57 ET | 6347 | 2.905 |
09:59 ET | 450 | 2.905 |
10:01 ET | 3800 | 2.8901 |
10:03 ET | 22966 | 2.895 |
10:06 ET | 2000 | 2.9 |
10:08 ET | 1310 | 2.895 |
10:10 ET | 19049 | 2.8889 |
10:12 ET | 9373 | 2.885 |
10:14 ET | 217635 | 2.8999 |
10:15 ET | 23161 | 2.9 |
10:17 ET | 18725 | 2.9 |
10:19 ET | 6931 | 2.89 |
10:21 ET | 7495 | 2.89 |
10:24 ET | 12470 | 2.89 |
10:26 ET | 7692 | 2.885 |
10:28 ET | 1200 | 2.885 |
10:30 ET | 1200 | 2.885 |
10:32 ET | 2900 | 2.885 |
10:33 ET | 500 | 2.885 |
10:35 ET | 1466 | 2.885 |
10:37 ET | 1600 | 2.885 |
10:39 ET | 900 | 2.885 |
10:42 ET | 12588 | 2.8708 |
10:44 ET | 300 | 2.875 |
10:46 ET | 7850 | 2.875 |
10:48 ET | 4640 | 2.865 |
10:50 ET | 500 | 2.86 |
10:51 ET | 900 | 2.865 |
10:53 ET | 1100 | 2.865 |
10:55 ET | 4300 | 2.865 |
10:57 ET | 500 | 2.865 |
11:00 ET | 2970 | 2.865 |
11:02 ET | 2090 | 2.865 |
11:04 ET | 162788 | 2.865 |
11:06 ET | 93923 | 2.875 |
11:08 ET | 18655 | 2.885 |
11:09 ET | 19647 | 2.9 |
11:11 ET | 3660 | 2.895 |
11:13 ET | 2600 | 2.895 |
11:15 ET | 2213 | 2.9 |
11:18 ET | 1611 | 2.895 |
11:20 ET | 1487 | 2.895 |
11:22 ET | 23640 | 2.93 |
11:24 ET | 5195 | 2.93 |
11:26 ET | 16279 | 2.915 |
11:27 ET | 500 | 2.91 |
11:29 ET | 16927 | 2.895 |
11:31 ET | 18344 | 2.905 |
11:33 ET | 3969 | 2.895 |
11:36 ET | 13145 | 2.9 |
11:38 ET | 100 | 2.9075 |
11:40 ET | 603 | 2.905 |
11:42 ET | 697 | 2.905 |
11:44 ET | 1469 | 2.905 |
11:45 ET | 2300 | 2.905 |
11:47 ET | 1303 | 2.905 |
11:49 ET | 18427 | 2.895 |
11:51 ET | 34616 | 2.92 |
11:54 ET | 500 | 2.92 |
11:56 ET | 100 | 2.915 |
11:58 ET | 400 | 2.915 |
12:00 ET | 1036 | 2.915 |
12:02 ET | 700 | 2.915 |
12:03 ET | 1341 | 2.915 |
12:05 ET | 1300 | 2.915 |
12:07 ET | 36928 | 2.915 |
12:09 ET | 900 | 2.915 |
12:12 ET | 1100 | 2.92 |
12:14 ET | 834 | 2.915 |
12:16 ET | 200 | 2.92 |
12:18 ET | 1061 | 2.915 |
12:20 ET | 400 | 2.91 |
12:21 ET | 721 | 2.915 |
12:23 ET | 500 | 2.915 |
12:25 ET | 744 | 2.915 |
12:27 ET | 4225 | 2.915 |
12:30 ET | 130461 | 2.94 |
12:32 ET | 2900 | 2.94 |
12:34 ET | 6518 | 2.935 |
12:36 ET | 1148 | 2.935 |
12:38 ET | 22305 | 2.945 |
12:39 ET | 1566 | 2.945 |
12:41 ET | 11005 | 2.925 |
12:43 ET | 4062 | 2.91 |
12:45 ET | 24319 | 2.895 |
12:48 ET | 1184 | 2.895 |
12:50 ET | 1668 | 2.9 |
12:52 ET | 4262 | 2.895 |
12:54 ET | 300 | 2.895 |
12:56 ET | 66946 | 2.9 |
12:57 ET | 6425 | 2.895 |
12:59 ET | 200 | 2.9 |
01:01 ET | 2675 | 2.895 |
01:03 ET | 2396 | 2.9 |
01:06 ET | 11011 | 2.895 |
01:08 ET | 700 | 2.9 |
01:10 ET | 3800 | 2.895 |
01:12 ET | 6833 | 2.895 |
01:14 ET | 6072 | 2.9 |
01:15 ET | 1700 | 2.895 |
01:17 ET | 4469 | 2.895 |
01:19 ET | 4488 | 2.9 |
01:21 ET | 2217 | 2.895 |
01:24 ET | 21131 | 2.885 |
01:26 ET | 5329 | 2.885 |
01:28 ET | 4095 | 2.885 |
01:30 ET | 3208 | 2.885 |
01:32 ET | 1893 | 2.885 |
01:33 ET | 35215 | 2.9 |
01:35 ET | 1200 | 2.9 |
01:37 ET | 1639 | 2.9 |
01:39 ET | 51134 | 2.905 |
01:42 ET | 1100 | 2.905 |
01:44 ET | 886 | 2.91 |
01:46 ET | 1200 | 2.91 |
01:48 ET | 1812 | 2.91 |
01:50 ET | 1295 | 2.905 |
01:51 ET | 200 | 2.905 |
01:53 ET | 200 | 2.91 |
01:55 ET | 580 | 2.91 |
01:57 ET | 2100 | 2.905 |
02:00 ET | 17987 | 2.905 |
02:02 ET | 2400 | 2.91 |
02:04 ET | 2200 | 2.91 |
02:06 ET | 222 | 2.905 |
02:08 ET | 100 | 2.91 |
02:09 ET | 100 | 2.905 |
02:11 ET | 400 | 2.91 |
02:13 ET | 4026 | 2.905 |
02:15 ET | 700 | 2.91 |
02:18 ET | 50656 | 2.915 |
02:20 ET | 849 | 2.915 |
02:22 ET | 700 | 2.92 |
02:24 ET | 805 | 2.92 |
02:26 ET | 1000 | 2.92 |
02:27 ET | 800 | 2.915 |
02:29 ET | 38159 | 2.9 |
02:31 ET | 3642 | 2.9 |
02:33 ET | 6569 | 2.895 |
02:36 ET | 500 | 2.895 |
02:38 ET | 1400 | 2.9 |
02:40 ET | 2187 | 2.895 |
02:42 ET | 3754 | 2.9 |
02:44 ET | 4800 | 2.895 |
02:45 ET | 2000 | 2.895 |
02:47 ET | 2253 | 2.9 |
02:49 ET | 1000 | 2.895 |
02:51 ET | 1600 | 2.9 |
02:54 ET | 1569 | 2.9 |
02:56 ET | 3651 | 2.9 |
02:58 ET | 3232 | 2.9 |
03:00 ET | 3091 | 2.9 |
03:02 ET | 2128 | 2.895 |
03:03 ET | 1600 | 2.895 |
03:05 ET | 5781 | 2.9 |
03:07 ET | 1998 | 2.895 |
03:09 ET | 1829 | 2.9 |
03:12 ET | 1400 | 2.895 |
03:14 ET | 5782 | 2.895 |
03:16 ET | 3497 | 2.895 |
03:18 ET | 4566 | 2.9 |
03:20 ET | 4536 | 2.895 |
03:21 ET | 11771 | 2.9 |
03:23 ET | 5358 | 2.9 |
03:25 ET | 3097 | 2.895 |
03:27 ET | 97259 | 2.895 |
03:30 ET | 7874 | 2.895 |
03:32 ET | 5085 | 2.895 |
03:34 ET | 61925 | 2.876 |
03:36 ET | 20354 | 2.86 |
03:38 ET | 14118 | 2.855 |
03:39 ET | 8497 | 2.855 |
03:41 ET | 7876 | 2.854 |
03:43 ET | 5879 | 2.855 |
03:45 ET | 21788 | 2.84 |
03:48 ET | 6068 | 2.845 |
03:50 ET | 139142 | 2.855 |
03:52 ET | 29685 | 2.855 |
03:54 ET | 14147 | 2.855 |
03:56 ET | 28532 | 2.855 |
03:57 ET | 13344 | 2.855 |
03:59 ET | 99521 | 2.855 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Allogene Therapeutics Inc | 519.0M | -1.4x | --- |
Celcuity Inc | 515.9M | -5.8x | --- |
Arrivent Biopharma Inc | 512.5M | -7.2x | --- |
Nkarta Inc | 503.3M | -2.8x | --- |
Phathom Pharmaceuticals Inc | 533.7M | -2.3x | --- |
Altimmune Inc | 501.9M | -4.4x | --- |
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $519.0M |
---|---|
Revenue (TTM) | $95.0K |
Shares Outstanding | 170.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.87 |
EPS | $-2.09 |
Book Value | $3.04 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 5,463.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -344,986.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.